Rachael Hawtin

Rachael Hawtin has over 17 years of experience in drug development, encompassing small molecules and biologics for oncology and autoimmune indications. She has held leadership positions in drug development programs spanning discovery biology through to clinical development in the context of both international companies and small biotechnology organizations. Prior to joining Nodality, she held various positions at Sunesis Pharmaceuticals, progressing to the lead role in the translational science component of two clinical stage programs. Rachael previously led the small molecule target discovery program at Chiron Corporation. Additionally, she held progressively responsible positions at Sugen Inc., where she served as leader of a protein expression technology group, and as leader of a small molecule oncology drug development program. Rachael completed her BSc at the University of Edinburgh, Scotland, and her PhD at the Institute of Virology and Environmental Microbiology (IVEM) in Oxford, England.